Chief Executive Officer, IntraBio Inc.
Appears in 1 story
Leading IntraBio through its second FDA approval
About 1 in 40,000 people are born with ataxia-telangiectasia, a genetic disease that destroys the cerebellum and progressively strips muscle control, typically starting in early childhood. Until this week, no drug was approved for it anywhere in the world. IntraBio's AQNEURSA (levacetylleucine) just became the first.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
